Core Viewpoint - Invivyd positions its monoclonal antibody VYD2311 as a potent alternative to COVID-19 vaccination, emphasizing its potential for "vaccine-free protection" against symptomatic COVID-19 [1] Company Focus and Pipeline - The company is advancing its REVOLUTION clinical program for VYD2311, continuing the commercialization of PEMGARDA, and exploring additional clinical indications, including long COVID and other infectious diseases like RSV and measles [2][13] - Invivyd has completed enrollment in the pivotal DECLARATION trial for VYD2311, with results expected in mid-2026 [6][9] Financial Performance - Invivyd raised over $200 million in the second half of 2025, ending the year with $226.7 million in cash, which supports operations through pivotal data expected in mid-2026 [4][17] - PEMGARDA's net revenues increased by 31% quarter-over-quarter and 25% year-over-year, totaling $53.4 million for the full year 2025, with a reorder rate of 77% among accounts [5][16] Clinical Trials and Safety Monitoring - The DECLARATION trial is a triple-blind randomized clinical trial evaluating VYD2311's safety and efficacy, with a target enrollment of approximately 1,770 subjects [6][7] - The Independent Data Monitoring Committee has reviewed early safety data and made recommendations regarding participant enrollment and monitoring [7][10] Commercial Strategy - Invivyd is seeing increased clinician interest in monoclonal antibodies for high-risk patients, with PEMGARDA included in guidelines from major health organizations [11][12] - The company is expanding its commercial footprint, with over 15,000 contracted GPO sites [5][14] Future Developments - Invivyd is excited to explore antibodies for long COVID and post-vaccination syndrome, with plans for updates on measles in the first half of the year [13][15]